A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia

Clinical trial NCT02858440 · COMPLETED

Trial details

NCT number: NCT02858440
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Diphtheria Tetanus Pertussis Hepatitis B Haemophilus Influenzae Type b

Start date: 2016-09-13
Primary completion: 2017-10-24
Enrollment: 235

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.